U.S. Department of Health and Human Services

FGF-23: An Interdisciplinary Dialog for Chronic Kidney Diseases

3/27/2017 12:00 AM
3/28/2017 12:00 AM

Program Content

Cindy Roy, Ph.D.
Program Director, Hematology
T: 301-594-8805
E: cindy.roy@nih.gov

Meeting Logistics

John Hare, CMP
The Scientific Consulting Group, Inc.
T: 301-670-4990
E: jhare@scgcorp.com
Lister Hill Auditorium

Event Details

Meeting Purpose

Patients with Chronic Kidney Diseases (CKDs) frequently experience disturbances of mineral metabolism resulting in systemic effects on the blood, bone, and vasculature. Iron and phosphate are important to maintain these systems; however, the biological signals controlling their regulation are only partly understood. Fibroblast Growth Factor 23 (FGF-23), a bone-derived hormone, regulates systemic phosphate homeostasis. Its discovery also has revealed novel interactions between phosphate and iron homeostasis. The NIDDK extramural research community offers a wealth of existing resources, infrastructure, and expertise that could accelerate the progress in this developing research area. Interdisciplinary approaches to understanding the physiologic and molecular regulators of phosphate and iron among patients with CKDs may identify novel diagnostic tools, new interventions, and improve clinical outcomes.​​​​​​​​

Organizing Committee

External Organizers
Tomas Ganz, M.D., Ph.D.; University of California, Los Angeles
Alan Go, M.D.; Kaiser Permanente Division of Research
Sharon Moe, M.D.; Indiana University
Orson Moe, M.D.; University of Texas Southwestern Medical Center
Isidro Salusky, M.D.; University of California, Los Angeles
Myles Wolf, M.D.; Duke University

NIH Organizers
Kevin Abbott, M.D., M.P.H.; NIDDK/KUH
Bonnie Burgess-Beusse, Ph.D.; NIDDK/DDN
Faye Chen, Ph.D.; NIAMS/DMD
Michael Flessner, M.D., Ph.D.; NIDDK/KUH
Daniel Gossett, Ph.D.; NIDDK/KUH
Chris Ketchum, Ph.D.; NIDDK/KUH
Paul Kimmel, M.D.; NIDDK/KUH
John Kusek, Ph.D.; NIDDK/KUH
Saul Malozowski, M.D., Ph.D., M.B.A.; NIDDK/DEM
Marva Moxey-Mims, M.D.; NIDDK/KUH
Cindy Roy, Ph.D.; NIDDK/KUH
Krystyna Rys-Sikora, Ph.D.; NIDDK/KUH
Jason Wan, Ph.D.; NIDCR/IBIDB
John Williams, Ph.D.; NIA/DAB​​​​

Registration Deadline

March 26, 2017​​​​


The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) acknowledges the support of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in the development of this joint program.

March 27, 2017

7:30 a.m. Registration and Poster Setup
8:00 a.m. Welcome
Griffin P. Rodgers, M.D., MACP, Director, NIDDK
Robert Star, M.D., Director, Division of Kidney, Urologic and Hematologic Diseases, NIDDK
8:20 a.m. Meeting Purpose and Logistics
Cindy Roy, Ph.D., NIDDK
8:40 a.m. Introduction, Barriers, Opportunities
Myles Wolf, M.D., Duke University
9:00 a.m. Session 1: What Is Fibroblast Growth Factor (FGF)-23? What Does It Do?
Moderator: Faye Chen, Ph.D., NIAMS
  FGF-23 and the Regulation of Phosphate Homeostasis
Kenneth White, Ph.D., Indiana University-Purdue University Indianapolis
  The Current State of Structural Biology of FGF-23 Signaling
Moosa Mohammadi, Ph.D., New York University
10:00 a.m. Break
10:30 a.m. Session 2: Measuring FGF-23 in Patients and Populations
Moderator: Jason Wan, Ph.D., National Institute of Dental and Craniofacial Research
Orson Moe, M.D., The University of Texas Southwestern Medical Center
Myles Wolf, M.D., Duke University
11:30 a.m. Lunch and Posters
12:30 p.m. Session 3: Impact of FGF-23 in Kidney Diseases 1
Moderator: Krystyna Rys-Sikora, Ph.D., NIDDK
  The Effects of Iron and Erythropoietin on FGF-23 Production
Tomas Ganz, M.D., Ph.D., University of California, Los Angeles
  FGF-23: Cross-talk Between Inflammation and Iron Metabolism
Nicolae Valentin David, Ph.D., Northwestern University
  FGF-23 and Bone in Chronic Kidney Disease (CKD)
Isidro Salusky, M.D., University of California, Los Angeles
2:00 p.m. Break
2:30 p.m. Session 4: Impact of FGF-23 in Kidney Diseases 2
Moderator: Pothur Srinivas, Ph.D., M.P.H., National Heart, Lung, and Blood Institute
  Direct Pathologic Actions of FGF-23 in CKD
Christian Faul, Ph.D., University of Miami
  FGF-23 and Cardiovascular Disease Risk in the Community: Insights from the Framingham Heart Study and an Overview of the Literature
Vasan Ramachandran, M.D., Framingham Heart Study/Boston University
  Impact of the FGF-23/α-Klotho/Phosphate Axis in Vascular Calcification
Cecilia Giachelli, Ph.D., University of Washington
  FGF-23 and Mortality in Critically Ill Patients
David Leaf, M.D., Brigham and Women’s Hospital
4:30 p.m. Discussion Session 1
Moderators: Myles Wolf, M.D., Duke University, and Chris Ketchum, Ph.D., NIDDK

March 28, 2017

7:30 a.m. Registration and Poster Setup
8:00 a.m. Introductions and Logistics
8:30 a.m. Session 5: Clinical Considerations
Moderator: Kevin Abbott, M.D., M.P.H., NIDDK
  FGF-23 Assays: Strengths and Limitations
Harald Jüppner, M.D., Massachusetts General Hospital
  Potential Role of FGF-23 in Improving Risk Stratification of and Prognosis for Clinical Outcomes in CKD
Alan Go, M.D., Kaiser Permanente
  Cardiovascular Disease in CKD—Not So Straightforward!
Sharon Moe, M.D., Indiana University
  Dietary Considerations for Patients and Trial Participants
Orlando Gutierrez, M.D., The University of Alabama at Birmingham
  Entry Criteria, Efficacy Endpoints and Safety Considerations: A Regulatory Perspective
Aliza Thompson, M.D., U.S. Food and Drug Administration
11:00 a.m. Session 6: Industry Panel
Moderators: Daniel Gossett, Ph.D., and Paul Kimmel, M.D., NIDDK
  Valerie Clerin, Ph.D., Pfizer, Inc.
Kerry Cooper, M.D., Amgen
Paul Korner, M.D., Ardelyx, Inc.
John F. Neylan, M.D., Keryx Biopharmaceuticals, Inc.
Amit Sharma, M.D., Akebia Therapeutics, Inc.
12:30 p.m. Lunch and Posters
1:30 p.m. Discussion Session 2
Moderators: Alan Go, M.D., Kaiser Permanente, and Paul Kimmel, M.D., NIDDK
2:30 p.m. Session 7: Therapeutics: Approaches to FGF-23
Moderator: Marva Moxey-Mims, M.D., NIDDK
  KRN23, a Fully Human Monoclonal Antibody to FGF-23, Reverses Renal Phosphate Wasting and Improves Bone Disease in Children and Adults with X-linked Hypophosphatemia (XLH)
Anthony Portale, M.D., University of California, San Francisco
  FGF-23-related Endpoints for Consideration in Future Clinical Trials Relevant to Adult and Pediatric CKD Populations
Tamara Isakova, M.D., Northwestern University
3:30 p.m. Discussion Session 3
Moderators: Sharon Moe, M.D., Indiana University, and John Kusek, Ph.D., NIDDK
4:30 p.m. Summary and Future Directions
Robert Star, M.D., Director, Division of Kidney, Urologic and Hematologic Diseases, NIDDK


Hotel Accommodations

Bethesda Marriott Hotel
5151 Pooks Hill Road
Bethesda, MD  20814
Phone:  (301) 897-9400 or (800) 228-9290
Fax: (301) 897-0192

Website:  http://www.bethesdamarriott.com
(More hotel information can be obtained from this website.)

Government Room Rate

A limited block of sleeping rooms for meeting participants has been reserved at the Bethesda Marriott Hotel. The rate is the prevailing government rate of $242 per night for single occupancy, plus tax (13%). To reserve a hotel room at the group rate, call reservations at (800) 228-9290 and identify yourself as a member of the FGF-23 Workshop or click on this link: to book your room. The room block will be in effect at the Government rate only until Sunday, February 26, 2017, or until full, whichever comes first. Any room reservations received after this date will be accepted on a space and rate-availability basis.

Reservation Dates

Book arrival on Sunday, March 26, 2017, and departure on Tuesday, March 28, 2017. If you require alternate dates, please contact John Hare of The Scientific Consulting Group, Inc. (SCG).


Please be certain that the hotel provides you with a confirmation number for your reservation. After February 26, 2017, the official room block will be released, and the hotel may charge significantly higher rates and may be sold out. When making a reservation, please provide your room and bedding preferences. The hotel will assign specific room types at check-in, based on availability. Please be advised that requests are not guaranteed. Check-in time is 4:00 p.m., and checkout time is 12:00 p.m.


If you need to cancel your reservation, please do so by 4:00 p.m. on the day prior to arrival, or you will be charged a no-show fee for 1 night on your credit card.

NIH Visitor Information 

Information on visiting the NIH, campus maps, shuttle schedules, driving directions, security, and more can be found on the NIH Visitor Information page. ​


Minutes are currently unavailable.


Attendees are currently unavailable.


Extended Submission Deadline: Friday, February 24, 2017
Notification of acceptance: March 1, 2017

Participants in the FGF-23 workshop, are encouraged to submit abstracts of their research activities. In addition to an opportunity to present their research in a poster session, conference attendees will find additional career development and networking opportunities with other researchers.

All abstracts must be submitted via email to John Hare of The Scientific Consulting Group, Inc. with “FGF-23 Abstract” in the subject line. Abstract submissions should be no longer than 250 words (not including name and affiliation).

Please follow the instructions below to submit an abstract for consideration: Download Template

  1. Indicate the career stage of the submitting author (student, fellow, instructor, assistant professor, etc)
  2. The abstract should be an MS Word document typed single-spaced using 12 point Times New Roman font. The abstract’s title should be Bold, 16 pt., Title Case font and should clearly represent the nature of the investigation. The title should be followed in lowercase letters by the author’s first and last names, degree, and affiliation, city, state, and country. Underline the primary author’s name (one primary author per abstract). Use one blank line between the title and the body of the abstract and between paragraphs. The abstract file should be saved as: primary authors’ last name_first word in the title (e.g., Zucker_Effects).
  3. Please ensure that your abstract is the correct length and use 1" margins
  4. Use of standard abbreviations is desirable (e.g., RBC) as well as standard symbols for units of measure (e.g., kg, gm, mg, mL, L, and %). Place a special or unusual abbreviation in parentheses after the full word the first time that it appears. Use numerals to indicate numbers except to begin sentences. Do not use subtitles (e.g., Methods, Results).
  5. 5. Simple tables or graphs may be included; however, they must fit within the designated abstract space of one page.

Please note that submissions for travel awards closed with the original abstract deadline of February 10, 2017. Junior level participants (students, fellows, instructors and assistant professors) with the highest scoring abstracts will be eligible for a modest travel award. Travel award notifications will be made by February 24, 2017.

Poster Presentations

Poster presentations will be displayed on 4-foot-high by 6-foot-wide poster boards. Pushpins and Velcro will be provided onsite. Please arrive between 7:30 and 8:00 a.m., March 27, 2017, to mount your poster on the posterboard and then remove your poster at the end of the meeting. You will be responsible for removing and shipping your poster.

All presenters must pre-register for the conference.


  • 8600 Rockville Pike
  • Building 38A, NIH Campus
  • MD 20894



Program Content

Cindy Roy, Ph.D.
Program Director, Hematology
T: 301-594-8805
E: cindy.roy@nih.gov

Meeting Logistics

John Hare, CMP
The Scientific Consulting Group, Inc.
T: 301-670-4990
E: jhare@scgcorp.com